glp-1 news today cardiovascular outcomes 2025 november Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Cardiovascular benefits of GLP-1 drugs

These are people who restrict severely, carry intense fear of weight gain, and meet every psychological criterion for anorexia nervosa, but whose body weight falls in a range that GLP-1 prescribers may read as an indication for treatment

Researchers working with multiple peptides simultaneously should be particularly careful about labeling

doi: 10.1007/s40265-023-01992-4 15

Discontinuation typically results in weight regain, with patients recovering approximately two-thirds of lost weight within 12 months after stopping treatment

In this context, the concept of biased agonism 37 has emerged, in which ligands can selectively engage in different intracellular pathways, potentially allowing specific cellular responses